Nocardiosis future or investigational therapies

Revision as of 18:11, 18 September 2017 by WikiBot (talk | contribs) (Changes made per Mahshid's request)
(diff) ← Older revision | Latest revision (diff) | Newer revision → (diff)
Jump to navigation Jump to search

Nocardiosis Microchapters

Home

Patient Information

Overview

Historical Perspective

Pathophysiology

Differentiating Nocardiosis from other Diseases

Epidemiology and Demographics

Causes

Risk Factors

Natural History, Complications and Prognosis

Diagnosis

History and Symptoms

Physical Examination

Laboratory Findings

X Ray

CT

MRI

Other Diagnostic Studies

Treatment

Medical Therapy

Surgery

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Nocardiosis future or investigational therapies On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Nocardiosis future or investigational therapies

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Nocardiosis future or investigational therapies

CDC on Nocardiosis future or investigational therapies

Nocardiosis future or investigational therapies in the news

Blogs on Nocardiosis future or investigational therapies

Directions to Hospitals Treating Nocardiosis

Risk calculators and risk factors for Nocardiosis future or investigational therapies

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]

Future or Investigational Therapies

A new combination drug therapy (sulfonamide, ceftriaxone, and amikacin) has shown promise for treatment of infections not responding to standard antimicrobial treatments. Application of newer molecular diagnostic and subtyping methods may assist in earlier diagnosis.

References

Template:WH Template:WS